Humanigen Stock Is Trading Higher As Lenzilumab Improves Survival In Hospitalized COVID-19 Patients

Humanigen Inc HGEN has reported topline data from Phase 3 study evaluating its lead drug candidate, lenzilumab, in patients hospitalized with COVID-19.

  • The 520-patient study demonstrated that lenzilumab significantly improved patient outcomes.
  • Results showed that patients who received lenzilumab and other treatments, including steroids and remdesivir, had a 54% greater relative likelihood of survival without the need for invasive mechanical ventilation compared to placebo.
  • The study achieved its primary endpoint of ventilator-free survival measured through day 28 following treatment. Invasive mechanical ventilation and/or death was 15.6% in the lenzilumab arm versus 22.1% in the placebo arm.
  • A favorable mortality trend was observed at 9.6% in the lenzilumab arm compared with 13.9% in the placebo arm.
  • Lenzilumab appeared to be safe and well-tolerated; no new SAEs were identified, and none were attributed to lenzilumab.
  • Price Action: HGEN shares are trading 65.7% higher at $23.18 in premarket on the last check Monday.

See also: Best Private Health Insurance 

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareSmall CapFDAGeneralCOVID-19 CoronavirusPhase 3 Study
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!